Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297275 | 1.00 | HTR4 (0.41) | HTR4S1PR1S1PR5POLBSCN4A | |
| SCHEMBL3948310 | 0.89 | KMT2A (0.47) | HTR4MEN1KMT2ADRD2DRD4 | |
| SCHEMBL13631063 | 0.89 | KMT2A (0.47) | HTR4MEN1KMT2ADRD2DRD4 | |
| SCHEMBL4353262 | 0.89 | KMT2A (0.47) | HTR4MEN1KMT2ADRD2DRD4 | |
| SCHEMBL15521125 | 0.85 | OGA (0.45) | HTR4S1PR1S1PR5POLBMEN1 | |
| SCHEMBL15521073 | 0.84 | UBE2M (0.39) | HTR4S1PR1S1PR5POLBMEN1 | |
| SCHEMBL1237636 | 0.84 | FUCA1 (0.45) | S1PR1S1PR5DRD2DRD3FUCA1 | |
| SCHEMBL6765544 | 0.84 | FUCA1 (0.45) | S1PR1S1PR5DRD2DRD3FUCA1 | |
| SCHEMBL1237635 | 0.84 | FUCA1 (0.45) | S1PR1S1PR5DRD2DRD3FUCA1 | |
| SCHEMBL8741125 | 0.82 | POLB (0.46) | S1PR1S1PR5POLBSCN4AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | HTR4 4125/4885S1PR1 3319/4885S1PR5 3614/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | HTR4 4514/4885S1PR1 4056/4885S1PR5 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.